There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Up until recently, the stock has been a chronic underperformer.

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high of $27.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer’s results,

They aren't just "pandemic stocks."

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines of care, one analyst said.